Published in Curr Pharm Des on January 01, 2007
Prenatal treatment prevents learning deficit in Down syndrome model. PLoS One (2012) 1.41
Molecular basis of pharmacotherapies for cognition in Down syndrome. Trends Pharmacol Sci (2009) 1.04
Mouse models of Down syndrome as a tool to unravel the causes of mental disabilities. Neural Plast (2012) 1.00
Oxidative Stress and Down Syndrome: A Route toward Alzheimer-Like Dementia. Curr Gerontol Geriatr Res (2011) 0.98
Prevention of developmental delays in a Down syndrome mouse model. Obstet Gynecol (2008) 0.94
The NAP motif of activity-dependent neuroprotective protein (ADNP) regulates dendritic spines through microtubule end binding proteins. Mol Psychiatry (2014) 0.90
Impairment of proteostasis network in Down syndrome prior to the development of Alzheimer's disease neuropathology: redox proteomics analysis of human brain. Biochim Biophys Acta (2013) 0.89
The neuroprotective peptide NAP does not directly affect polymerization or dynamics of reconstituted neural microtubules. J Alzheimers Dis (2010) 0.86
Antioxidants in Down syndrome. Biochim Biophys Acta (2011) 0.85
Cognitive and pharmacological insights from the Ts65Dn mouse model of Down syndrome. Curr Opin Neurobiol (2012) 0.83
Chronic P7C3 treatment restores hippocampal neurogenesis in the Ts65Dn mouse model of Down Syndrome [Corrected]. Neurosci Lett (2015) 0.75
Alzheimer's presenilin 1 mutations impair kinesin-based axonal transport. J Neurosci (2003) 1.91
Altered metabolism of the amyloid beta precursor protein is associated with mitochondrial dysfunction in Down's syndrome. Neuron (2002) 1.82
Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1. Br J Pharmacol (2012) 1.64
Relevance of the thyroid hormones-αvβ3 pathway in primary myeloma bone marrow cells and to bortezomib action. Leuk Lymphoma (2014) 1.43
A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. J Pharmacol Exp Ther (2008) 1.41
Activity-dependent neuroprotective protein: a novel gene essential for brain formation. Brain Res Dev Brain Res (2003) 1.38
Phosphorylation of actin-depolymerizing factor/cofilin by LIM-kinase mediates amyloid beta-induced degeneration: a potential mechanism of neuronal dystrophy in Alzheimer's disease. J Neurosci (2006) 1.35
Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model. J Pharmacol Exp Ther (2007) 1.30
NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model. Neurobiol Dis (2009) 1.26
Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage. J Mol Neurosci (2007) 1.24
Differential effects of ethanol antagonism and neuroprotection in peptide fragment NAPVSIPQ prevention of ethanol-induced developmental toxicity. Proc Natl Acad Sci U S A (2003) 1.23
Activity-dependent neuroprotective protein (ADNP) differentially interacts with chromatin to regulate genes essential for embryogenesis. Dev Biol (2006) 1.14
Hepcidin, a key regulator of iron metabolism, is transcriptionally activated by p53. Br J Haematol (2007) 1.13
A femtomolar acting octapeptide interacts with tubulin and protects astrocytes against zinc intoxication. J Biol Chem (2004) 1.12
Activity-dependent neuroprotective protein constitutes a novel element in the SWI/SNF chromatin remodeling complex. J Biol Chem (2007) 1.12
ets-2 promotes the activation of a mitochondrial death pathway in Down's syndrome neurons. J Neurosci (2005) 1.09
Peptide neuroprotection through specific interaction with brain tubulin. J Neurochem (2006) 1.08
PolyADP-ribosylation is involved in neurotrophic activity. J Neurosci (2005) 1.06
Thyroid hormones and cancer: clinical studies of hypothyroidism in oncology. Curr Opin Endocrinol Diabetes Obes (2010) 1.05
PolyADP-ribosylation is required for long-term memory formation in mammals. J Neurochem (2009) 1.03
NAP, a femtomolar-acting peptide, protects the brain against ischemic injury by reducing apoptotic death. Stroke (2002) 1.01
Novel peptides prevent alcohol-induced spatial learning deficits and proinflammatory cytokine release in a mouse model of fetal alcohol syndrome. Am J Obstet Gynecol (2005) 1.00
Neuroprotective protein and carboxypeptidase E. J Mol Neurosci (2009) 0.99
A role for thrombospondin-1 deficits in astrocyte-mediated spine and synaptic pathology in Down's syndrome. PLoS One (2010) 0.98
A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions. Mol Cell Neurosci (2010) 0.98
ADNP differential nucleus/cytoplasm localization in neurons suggests multiple roles in neuronal differentiation and maintenance. J Mol Neurosci (2008) 0.98
Brain deficits associated with fetal alcohol exposure may be protected, in part, by peptides derived from activity-dependent neurotrophic factor and activity-dependent neuroprotective protein. Brain Res Rev (2006) 0.97
2-Amino-3,4-dihydroquinazolines as inhibitors of BACE-1 (beta-site APP cleaving enzyme): Use of structure based design to convert a micromolar hit into a nanomolar lead. J Med Chem (2007) 0.97
Protective peptides that are orally active and mechanistically nonchiral. J Pharmacol Exp Ther (2004) 0.97
Subcellular localization and secretion of activity-dependent neuroprotective protein in astrocytes. Neuron Glia Biol (2004) 0.96
Activity-dependent neurotrophic factor-9 and NAP promote neurite outgrowth in rat hippocampal and cortical cultures. J Mol Neurosci (2005) 0.95
Activity-dependent neuroprotective protein (ADNP) expression level is correlated with the expression of the sister protein ADNP2: deregulation in schizophrenia. Eur Neuropsychopharmacol (2010) 0.95
Programmed acute electrical stimulation of ventral tegmental area alleviates depressive-like behavior. Neuropsychopharmacology (2008) 0.94
NAP (davunetide) modifies disease progression in a mouse model of severe neurodegeneration: protection against impairments in axonal transport. Neurobiol Dis (2013) 0.94
Davunetide (NAP) as a preventative treatment for central nervous system complications in a diabetes rat model. Neurobiol Dis (2011) 0.93
p53--a key player in tumoral and evolutionary adaptation: a lesson from the Israeli blind subterranean mole rat. Cell Cycle (2005) 0.93
Intranasal administration of NAP, a neuroprotective peptide, decreases anxiety-like behavior in aging mice in the elevated plus maze. Neurosci Lett (2004) 0.92
Cathepsins B and L differentially regulate amyloid precursor protein processing. J Pharmacol Exp Ther (2008) 0.92
NAP, a peptide derived from the activity-dependent neuroprotective protein, modulates macrophage function. Ann N Y Acad Sci (2006) 0.91
The ADNP derived peptide, NAP modulates the tubulin pool: implication for neurotrophic and neuroprotective activities. PLoS One (2012) 0.90
Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy. Neuropsychiatr Dis Treat (2012) 0.90
Novel evolutionary-conserved role for the activity-dependent neuroprotective protein (ADNP) family that is important for erythropoiesis. J Biol Chem (2012) 0.90
Blockage of VIP during mouse embryogenesis modifies adult behavior and results in permanent changes in brain chemistry. J Mol Neurosci (2007) 0.89
Assessment of the response to imatinib in chronic myeloid leukemia patients--comparison between the FISH, multiplex and RT-PCR methods. Eur J Haematol (2004) 0.89
From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP: a view of neuroprotection and cell division. J Mol Neurosci (2003) 0.88
The peptides ADNF-9 and NAP increase survival and neurite outgrowth of rat retinal ganglion cells in vitro. Invest Ophthalmol Vis Sci (2005) 0.88
Vasoactive intestinal peptide in the brain of a mouse model for Down syndrome. Exp Neurol (2003) 0.87
NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse--a microtubule-deficient model of schizophrenia. Peptides (2010) 0.87
NAP protects against cytochrome c release: inhibition of the initiation of apoptosis. Eur J Pharmacol (2009) 0.87
Carisbamate, a novel neuromodulator, inhibits voltage-gated sodium channels and action potential firing of rat hippocampal neurons. Epilepsy Res (2008) 0.87
The neuroprotective peptide NAP inhibits the aggregation of the beta-amyloid peptide. Peptides (2003) 0.86
Activity-dependent neuroprotective protein (ADNP) expression in the amyloid precursor protein/presenilin 1 mouse model of Alzheimer's disease. J Mol Neurosci (2009) 0.86
Differential regulation of activity-dependent neuroprotective protein in rat astrocytes by VIP and PACAP. Regul Pept (2004) 0.86
Tau and caspase 3 as targets for neuroprotection. Int J Alzheimers Dis (2012) 0.86
Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects. Curr Pharm Des (2011) 0.86
Vasoactive intestinal peptide receptors: a molecular target in breast and lung cancer. Curr Pharm Des (2007) 0.85
Neonatal mice of the Down syndrome model, Ts65Dn, exhibit upregulated VIP measures and reduced responsiveness of cortical astrocytes to VIP stimulation. J Mol Neurosci (2006) 0.85
Learning enhancement with neuropeptides. Am J Obstet Gynecol (2006) 0.85
NAP enhances neurodevelopment of newborn apolipoprotein E-deficient mice subjected to hypoxia. J Pharmacol Exp Ther (2006) 0.85
A vasoactive intestinal peptide receptor analog alters the expression of homeobox genes. Life Sci (2002) 0.84
Involvement of pituitary adenylate cyclase activating polypeptide (PACAP) and its receptors in the mechanism of antidepressant action. J Mol Neurosci (2008) 0.84
Complex array of cytokines released by vasoactive intestinal peptide. Neuropeptides (2003) 0.84
Silencing of the ADNP-family member, ADNP2, results in changes in cellular viability under oxidative stress. J Neurochem (2007) 0.84
(N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist. J Mol Neurosci (2002) 0.83
Thyroid hormone is a MAPK-dependent growth factor for human myeloma cells acting via αvβ3 integrin. Mol Cancer Res (2011) 0.83
NAP protects hippocampal neurons against multiple toxins. Peptides (2007) 0.83
The expression of activity-dependent neuroprotective protein (ADNP) is regulated by brain damage and treatment of mice with the ADNP derived peptide, NAP, reduces the severity of traumatic head injury. Curr Alzheimer Res (2005) 0.82
The microtubule interacting drug candidate NAP protects against kainic acid toxicity in a rat model of epilepsy. J Neurochem (2009) 0.82
The role of activity-dependent neuroprotective protein in a mouse model of fetal alcohol syndrome. Am J Obstet Gynecol (2003) 0.82
The pregnant spontaneously hypertensive rat as a model of asymmetric intrauterine growth retardation and neurodevelopmental delay. Hypertens Pregnancy (2005) 0.82
The expression of p53-target genes in the hypoxia-tolerant subterranean mole-rat is hypoxia-dependent and similar to expression patterns in solid tumors. Cell Cycle (2010) 0.82
Comparative analysis of the behavioral and biomolecular parameters of four mouse strains. J Mol Neurosci (2011) 0.81
Antagonism of VIP-stimulated cyclic AMP formation in chick brain. J Mol Neurosci (2003) 0.81
Novel glycosylated VIP analogs: synthesis, biological activity, and metabolic stability. J Pept Sci (2008) 0.81
Reduction of dominant or submissive behaviors as models for antimanic or antidepressant drug testing: technical considerations. J Neurosci Methods (2007) 0.81
Tubulin is the target binding site for NAP-related peptides: ADNF-9, D-NAP, and D-SAL. J Mol Neurosci (2006) 0.81
Microtubule-stabilizing peptides and small molecules protecting axonal transport and brain function: focus on davunetide (NAP). Neuropeptides (2013) 0.81
VIP provides cellular protection through a specific splice variant of the PACAP receptor: a new neuroprotection target. Peptides (2006) 0.81
Identification of eukaryotic elongation factor-2 as a novel cellular target of lithium and glycogen synthase kinase-3. Mol Cell Neurosci (2010) 0.81
The effects of vascular intrauterine growth retardation on cortical astrocytes. J Matern Fetal Neonatal Med (2010) 0.81
New horizons in schizophrenia treatment: autophagy protection is coupled with behavioral improvements in a mouse model of schizophrenia. Autophagy (2014) 0.81
NAP protects against cyanide-related microtubule destruction. J Neural Transm (Vienna) (2009) 0.80
Neuropeptide receptor transcripts are expressed in the rat clitoris and oscillate during the estrus cycle in the rat vagina. Peptides (2005) 0.80
Looking for novel ways to treat the hallmarks of Alzheimer's disease. Expert Opin Investig Drugs (2007) 0.80
D-NAP prophylactic treatment in the SOD mutant mouse model of amyotrophic lateral sclerosis: review of discovery and treatment of tauopathy. J Mol Neurosci (2012) 0.79
Sexual dimorphism of activity-dependent neuroprotective protein in the mouse arcuate nucleus. Neurosci Lett (2005) 0.79
High-throughput siRNA-based functional target validation. J Biomol Screen (2004) 0.79